C-c(=x)-x-c Containing (x Is Chalcogen And At Least One X Is Other Than Oxygen) Patents (Class 514/513)
-
Patent number: 8163797Abstract: The present invention provides oral pravastatin formulations comprising a physical mixture of pravastatin and at least one pharmaceutically-acceptable excipient, wherein the composition for at least 6 months after its preparation is stable and has a pH of greater than about 7 to less than 9, as well as methods for the preparation and use of these stable formulations.Type: GrantFiled: May 7, 2004Date of Patent: April 24, 2012Assignee: Actavis Elizabeth LLCInventor: Alfred Liang
-
Patent number: 8138158Abstract: Compositions and methods for therapy of cystic fibrosis, asthma, and other conditions characterized by defective chloride transport are provided. The compositions comprise one or more compounds such as flavones and/or isoflavones, ascorbate and/or derivatives thereof capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compositions to a patient afflicted with cystic fibrosis, asthma, and/or another condition responsive to stimulation of chloride transport.Type: GrantFiled: March 11, 2010Date of Patent: March 20, 2012Assignee: Children's Hospital & Research Center at OaklandInventors: Horst Fischer, Beate Illek
-
Patent number: 8084496Abstract: Resveratrol ferulate compounds and compositions.Type: GrantFiled: May 6, 2010Date of Patent: December 27, 2011Assignee: ELC Management LLCInventors: Daniel H. Maes, Fatemeh Mohammadi, Lisa Qu, Anna Czarnota, Thomas Mammone, Lieve Declercq, Julius R. Zecchino
-
Patent number: 8080583Abstract: An emulsion cosmetic composition comprising at least one resveratrol derivative, a water phase, and an oil phase containing at least one linear or branched volatile or near volatile silicone and a method for delivering active resveratrol to the skin.Type: GrantFiled: May 27, 2008Date of Patent: December 20, 2011Assignee: ELC Management LLCInventors: Daniel H. Maes, Fatemeh Mohammadi, Lisa Qu, Anna Czarnota, Thomas Mammone, Lieve Declercq, Julius R. Zecchino
-
Patent number: 8076372Abstract: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.Type: GrantFiled: March 30, 2009Date of Patent: December 13, 2011Assignee: Government of the United StatesInventors: John K. Inman, Atul Goel, Ettore Appella, Jim A. Turpin, Marco Schito
-
Publication number: 20110288168Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, genetic disorders, e.g. Huntington's disease and spinal muscular atrophy and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.Type: ApplicationFiled: November 29, 2010Publication date: November 24, 2011Inventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L. Wiech
-
Patent number: 8048452Abstract: A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.Type: GrantFiled: June 2, 2006Date of Patent: November 1, 2011Assignee: Bend Research, Inc.Inventors: William J. Curatolo, Dwayne T. Friesen, Michael J. Gumkowski, Douglas A. Lorenz, James A. S. Nightingale, Roger B. Ruggeri, Ravi M. Shanker
-
Publication number: 20110245262Abstract: Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: August 20, 2007Publication date: October 6, 2011Inventors: Lijun Sun, Keizo Koya, Shoujun Chen, Zachary Demko, Zhi-Qiang Xia
-
Patent number: 8026393Abstract: The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved.Type: GrantFiled: January 23, 2007Date of Patent: September 27, 2011Assignees: Sucampo AG, R-Tech Ueno, Ltd.Inventors: Yukiko Hashitera, Ryu Hirata, Yasuhiro Harada, Ryuji Ueno
-
Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof
Patent number: 8026231Abstract: The invention relates to novel aminothiol ester compounds having the general formula (I): and to a method for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (cancers and precancers, dermatological, rheumatic and ophthalmological complaints in particular) or in cosmetic compositions. The invention also relates to a pharmaceutical or cosmetic composition, characterized in that it comprises, as active agent, a compound of general formula (I) in combination with a pharmaceutically or cosmetically acceptable support.Type: GrantFiled: March 28, 2006Date of Patent: September 27, 2011Assignee: CNRSInventors: Guy Fournet, Gerard Anthony Quash, Jacques Gore -
Publication number: 20110224156Abstract: The invention relates to propionic acids, propionic acid esters, and related compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).Type: ApplicationFiled: March 8, 2011Publication date: September 15, 2011Inventors: Mark A. Wolf, Keith D. Barnes
-
Patent number: 8008347Abstract: The present invention is directed generally to protecting cells, tissues and organs against the damaging effects of ionizing or other damaging agents associated with radiation or chemotherapy, or degenerative diseases or processes of various organs that elicit the production of free radicals or oxidants such as peroxides, superoxide anions, hydroxyl radicals or nitric oxides, or heavy metal cations. More particularly, the present invention is concerned with methoxypolyethylene glycol thioester chelate methyl esters that are useful as protectors against tissue damage by penetrating the cell membrane to donate electrons to free radical oxidants and remove heavy metals that may react with peroxides to produce the reactive hydroxyl radical, or remove Ca++ that may be released from organelles. These chelate esters will also have utility in reducing intraocular pressure in glaucoma patients.Type: GrantFiled: February 14, 2007Date of Patent: August 30, 2011Assignee: Eastern Virginia Medical SchoolInventors: Karl A. Schellenberg, Frank A. Lattanzio, James Shaeffer
-
Publication number: 20110196034Abstract: A new vegetable, referred to herein as green garlic, grown from garlic bulbils is disclosed. In particular examples, the green garlic is rich in one or more thiosulfinates. Methods of producing green garlic are also disclosed. In some examples, such methods permit year-round commercial production of green garlic.Type: ApplicationFiled: April 8, 2011Publication date: August 11, 2011Inventors: Alpert P. Kausch, Peter Sellew
-
Publication number: 20110190368Abstract: Organosulfur compounds of the general formula (2) are described, wherein R1 and R2 are linear or branched C1-C5 alkyl; linear or branched C1-C5 alkenyl with the proviso that R1 is not prop-1-enyl (allyl); substituted linear or branched C1-C5 alkenyl or substituted linear or branched C1-C5 alkyl, in which the substituents are selected from OR3, NR4R5, COOR6, CON—R7R8, in which R3 is selected from H, COR9, para-methoxybenzyl and trialkylsilyl, in which R9 is alkyl or substituted alkyl; R4 N and R5 are alkyl or R4 and R5 together form a phthalimido group; R6 is alkyl or substituted alkyl; and R7 and R8 are alkyl or substituted alkyl; substituted or unsubstituted aromatic specifically where R1 and R2 are benzyl, para-methoxybenzyl and/or ortho,para-methoxybenzyl and substituted or unsubstituted heteroaromatic. The compounds can be used for inhibiting the growth of tumour cells and for treating cancer. A pharmaceutical composition and a method of preparing the compounds are also described.Type: ApplicationFiled: August 5, 2009Publication date: August 4, 2011Applicant: University of Cape TownInventors: Catherine Hart Kaschula, Roger Hunter, Mohamed Iqbal Parker
-
Patent number: 7985772Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.Type: GrantFiled: June 14, 2010Date of Patent: July 26, 2011Assignee: UCB Pharma GmbHInventors: Claus Meese, Bengt Sparf
-
Publication number: 20110178108Abstract: A group of amino substituted benzoyl derivatives, their preparation and their use. The screening and research on an antiviral drug with hA3G/Vif as a target point proves that the 3-amino benzoyl derivatives not only have the combined activity for the hA3G/Vif, but also have a function of inhibiting replication of viruses. The present invention provides the possible breakthrough progress for the problem of HIV drug resistance, thereby providing a novel clinical antiviral drug which has higher efficiency.Type: ApplicationFiled: September 28, 2009Publication date: July 21, 2011Applicant: Institute of Medicinal Biotechnology Academy of Medical ScienceInventors: Jian-Dong Jiang, Liyan Yu, Shan Cen, Zhourong Li, Yanping Li, Jlan Xu
-
Patent number: 7977378Abstract: Compositions and methods are provided for the treatment of obesity in a human in need of such treatment which comprises administration to the human of a therapeutically effective amount of a compound of a weight loss enhancing beta-3-adrenergic compound of Cycle I, and a different weight loss enhancing adenylate cyclase receptor replenishing compound of Cycle II, in conjunction with a pharmaceutically acceptable diluent or carrier, wherein the Compound of Cycle I and the compound of Cycle II are administered sequentially. The composition may be present as a kit having each sequence in blister packs.Type: GrantFiled: December 19, 2007Date of Patent: July 12, 2011Inventor: Adel Villalobos
-
Patent number: 7915237Abstract: The invention relates to pharmaceutical formulations containing exo/exo-tricyclo[5.2.1.02.6]-dec-9-yl-xanthogenate, drugs containing exo/exo-tricyclo[5.2.1.02.6]-dec-9-yl-xanthogenate as active ingredient for the treatment of genital herpes, labial herpes, AIDS, tumors or autoimmune diseases, and methods for the production of pure stereoisomers of tricyclo[5.2.1.02.6]-decan-9-ol and tricyclo[5.2.1.02.6]-dec-9-yl-xanthogenate.Type: GrantFiled: November 2, 2002Date of Patent: March 29, 2011Assignee: Lumavita AGInventor: Eberhard Amtmann
-
Patent number: 7897598Abstract: Analogs that inhibit the transport of anandamide across cell membranes. The inhibitors are amide and ester analogs of anandamide having a tail portion X that is a fatty acid chain remnant, a central portion Y that is an amide or ester radical and a head portion Z that is selected from a variety of groups including hydrogen, alkyl, hydroxy alkyl, aryl, hydroxy aryl, heterocyclic and hydroxy heterocyclic radicals. The disclosed analogs have potential pharmaceutical uses as drugs for treating a variety of diseases and afflictions, including cardiovascular diseases and blood pressure disorders.Type: GrantFiled: June 6, 1999Date of Patent: March 1, 2011Inventors: Alexandros Makriyannis, Sonyuan Lin, Daniele Piomelli
-
Patent number: 7846903Abstract: A cubic liquid crystal composition comprising at least one amphiphilic compound having the following general formula (1) and having an IV/OV value of 0.65 to 0.95, and water or an aqueous medium: wherein R represents a hydrophilic group; X and Y each independently represent a hydrogen atom or together form an oxygen atom; n is an integer of 0 to 4; and m is an integer of 0 to 3.Type: GrantFiled: October 19, 2005Date of Patent: December 7, 2010Assignees: National Institute of Advanced Industrial Science and Technology, Kuraray Co., Ltd., Cytopathfinder, Inc.Inventors: Masakatsu Hato, Yoshiji Fujita, Toshitaka Ota, Masahisa Tanomura, Manzo Shiono
-
Publication number: 20100286073Abstract: The present invention relates to compounds, as well as to compositions, methods and kits comprising such compounds, for use in the treatment or prophylaxis of fibromyalgia, chronic fatigue syndrome, myofascial pain syndrome, Gulf War syndrome and related conditions, wherein the compound is a fatty acid oxidation inhibitor and/or a carbohydrate oxidation activator.Type: ApplicationFiled: October 3, 2008Publication date: November 11, 2010Inventor: Paul JENKINS
-
Patent number: 7829564Abstract: ?-and ?-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.Type: GrantFiled: December 7, 2007Date of Patent: November 9, 2010Assignee: G.D. Searle LLCInventors: Michael L. Vazquez, Richard A. Mueller, John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, John N. Freskos, Robert M. Heintz, Deborah E. Bertenshaw
-
Publication number: 20100267801Abstract: Sulphones of formula (I) are disclosed for use in treatment of cancer.Type: ApplicationFiled: May 16, 2006Publication date: October 21, 2010Inventors: Huw David Lewis, Timothy Harrison, Mark Steven Shearman
-
Patent number: 7781484Abstract: Thiol ester compositions, methods of making the thiol ester compositions, and methods of using the thiol ester compositions are provided. In some embodiments, the thiol ester compositions include thiol esters, hydroxy thiol esters and cross-linked thiol esters. The thiol ester composition can be used to produce cross-linked thiol esters, sulfonic acid-containing esters, sulfonate containing esters and thioacrylate containing esters. The thiol ester compositions can be used to produce polythiourethanes. The polythiourethanes can be used in fertilizers and fertilizer coatings.Type: GrantFiled: February 17, 2005Date of Patent: August 24, 2010Assignee: Chevron Phillips Chemical Company LPInventors: Jim D. Byers, Mitchell D. Refvik, Chad W. Brown
-
Publication number: 20100152289Abstract: There is provided an organic sulfur compound having an excellent controlling effect on harmful arthropods which is represented by formula (I): wherein R1 represents a C3-C6 haloalkyl group having at least one fluorine atom and at least one atom selected from group consisting of a chlorine atom, a bromine atom and an iodine atom, R2 represents a cyano group and the like, R3 represents a hydrogen atom, a halogen atom or a C1-C4 alkyl group, R4 represents a C1-C5 fluoroalkyl group, and n represents 0, 1 or 2.Type: ApplicationFiled: May 18, 2008Publication date: June 17, 2010Inventor: Hiroyuki Miyazaki
-
Publication number: 20100130507Abstract: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.Type: ApplicationFiled: November 6, 2009Publication date: May 27, 2010Applicant: NICOX S.A.Inventors: Ennio ONGINI, Valerio Chiroli, Francesca Benedini, Piero Del Soldato
-
Patent number: 7718694Abstract: Compositions and methods for therapy of cystic fibrosis, asthma, and other conditions characterized by defective chloride transport are provided. The compositions comprise one or more compounds such as flavones and/or isoflavones, ascorbate and/or derivatives thereof capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compositions to a patient afflicted with cystic fibrosis, asthma, and/or another condition responsive to stimulation of chloride transport.Type: GrantFiled: January 30, 2004Date of Patent: May 18, 2010Assignee: Children's Hospital & Research Center at OaklandInventors: Horst Fischer, Beate Illek
-
Publication number: 20100105685Abstract: The present invention is directed to a method of treating a lack of normal breathing control including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions. In an aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a single compound which treats lack of normal breathing. In another aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a combination of two or more compounds, at least one of which treats lack of normal breathing. In an aspect, a compound is an S-nitrosylating agent.Type: ApplicationFiled: October 3, 2007Publication date: April 29, 2010Inventor: James C. Mannion
-
Publication number: 20100047327Abstract: It is intended to provide a low molecular weight adjuvant which can be administered safely without inducing skin irritation or the like by transdermal or transmucosal administration and is for enhancing immunogenicity of an antigen efficiently. It can be achieved by an immunostimulant adjuvant containing at least one substance selected from the group consisting of aliphatic alcohols, free fatty acids and fatty acid derivatives but does not contain a substance represented by the following formula. (In the formula, R3 and R4 may be combined to form a cyclic ring, and R1 and R2 independently represent an alkyl side chain having 1 to 16 carbon atoms.Type: ApplicationFiled: January 31, 2008Publication date: February 25, 2010Inventors: Tetsuji Kuwahara, Seiji Tokumoto, Toshiyuki Matsudo
-
Patent number: 7652042Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: GrantFiled: June 2, 2008Date of Patent: January 26, 2010Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Publication number: 20090312358Abstract: The present invention is directed to methods of treatment and/or management of diarrhea, such as chronic diarrhea using sequential administration of opioid agonists to suppress gut mobility and opioid antagonists to reverse the effect to controllably allow bowel movements. The agonists and antagonists are administered with a time interval in between the administration or between the release of the drugs from a pharmaceutical composition. The invention is further directed to methods of controlling, treating or managing side effects caused by the opioid agonists, specifically the side effects resulting from mast cell activation and/or granulation.Type: ApplicationFiled: March 22, 2007Publication date: December 17, 2009Applicant: TRUSTEES OF BOSTON UNIVERSITYInventor: Fouad A. Siddiqi
-
Patent number: 7629364Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: GrantFiled: June 2, 2008Date of Patent: December 8, 2009Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Patent number: 7625948Abstract: A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1?) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6alkyl or C1-C6alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R8 and R9 are each independently hydrogen atom, C1-C6alkyl, —CON(R18)(R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.Type: GrantFiled: February 28, 2003Date of Patent: December 1, 2009Assignee: Japan Tobacco Inc.Inventors: Atsushi Hagiwara, Yasuhiro Ohe, Naoya Odani, Shizue Watanabe, Taku Ikenogami, Takashi Kawai, Kenya Madono, Toshio Taniguchi
-
Patent number: 7585856Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.Type: GrantFiled: August 12, 2003Date of Patent: September 8, 2009Assignee: The Brigham and Women's Hospital, Inc.Inventor: Charles N. Serhan
-
Patent number: 7560484Abstract: The present invention provides an adjuvant that is a hydroxy unsaturated fatty acid or a derivative thereof, as well as a vaccine preparation containing the adjuvant as a constituent.Type: GrantFiled: August 28, 2001Date of Patent: July 14, 2009Assignee: The Kitasato InstituteInventors: Haruki Yamada, Hiroaki Kiyohara, Takayuki Nagai, Toshiaki Sunazuka
-
Patent number: 7537759Abstract: The invention provides methods and compositions relating to Kuz involvement in angiogenesis.Type: GrantFiled: March 21, 2005Date of Patent: May 26, 2009Assignee: The Regents of the University of CaliforniaInventors: Duojia Pan, Gerald M. Rubin, Hongbing Zhang
-
Patent number: 7538140Abstract: A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1?) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6alkyl or C1-C6alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R8 and R9 are each independently hydrogen atom, C1-C6alkyl, —CON(R18)(R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.Type: GrantFiled: February 28, 2003Date of Patent: May 26, 2009Assignee: Japan Tobacco IncInventors: Atsushi Hagiwara, Yasuhiro Ohe, Naoya Odani, Shizue Watanabe, Taku Ikenogami, Takashi Kawai, Kenya Madono, Toshio Taniguchi
-
Patent number: 7528274Abstract: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.Type: GrantFiled: July 25, 2002Date of Patent: May 5, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: John K. Inman, Atul Goel, Ettore Appella, Jim Turpin, Marco Schito
-
Patent number: 7491844Abstract: Described herein are compounds having a formula and therapeutic methods, compositions, and medicaments, related thereto.Type: GrantFiled: April 20, 2007Date of Patent: February 17, 2009Assignee: Allergan, Inc.Inventors: Yariv Donde, Jeremiah H. Nguyen
-
Patent number: 7485320Abstract: A liposome formulation for stably incorporating high content of hydrophobic substance is disclosed. The liposome includes two phospholipids with different phase transition temperatures such as saturated and unsaturated phosphatidyl cholines, hydrophobic substances, cholesterol, cholesterol derivatives, antioxidant and hydrophilic polymer-modified lipids such as MPEG-DSPE.Type: GrantFiled: July 23, 2003Date of Patent: February 3, 2009Assignee: Industrial Technology Research InstituteInventors: Pei Kan, Ae-June Wang, Won-Ko Chen, Chih-Wan Tsao
-
Patent number: 7482378Abstract: The present invention provides, in one aspect, a physiological cooling composition comprising at least one cyclohexane carboxamide, at least one acyclic carboxamide, and at least one stereoisomer of menthyl lactate. In another aspect, disclosed is a method for producing such composition. In still another aspect, disclosed are various consumer products comprising a physiological cooling composition comprising at least one cyclohexane carboxamide, at least one acyclic carboxamide, and at least one stereoisomer of menthyl lactate.Type: GrantFiled: May 28, 2004Date of Patent: January 27, 2009Assignee: Millenium Specialty Chemicals, Inc.Inventors: Mark B. Erman, Patrick J. Whelan, Joe W. Snow
-
Patent number: 7476755Abstract: Therapeutic substituted cyclopentane compounds, and compositions, medicaments, and therapeutic methods related thereto are disclosed herein.Type: GrantFiled: April 27, 2007Date of Patent: January 13, 2009Assignee: Allergan, Inc.Inventors: Yariv Donde, Jeremiah H. Nguyen
-
Publication number: 20090005445Abstract: Articles comprising one or more calcium salts are provided. The articles can contain one or more calcium salts in an amount effective to reduce the production of TSST-1 by at least about 50% when measured by the Shake Flask Method. In certain embodiments, the one or more calcium salts can be substantially non-lethal to Staphylococcus aureus when measured by the Shake Flask Method, and/or to Lactobacillus crispatus, Lactobacillus gasseri, and/or Lactobacillus iners when measured by the Maximum Tolerated Dose Test.Type: ApplicationFiled: June 28, 2007Publication date: January 1, 2009Inventors: Thomas Ward Osborn, III, Fancheng Wang, Kimberly Ann Nemeth, Catherine Cornick Davis
-
Publication number: 20080300303Abstract: The present invention pertains to substances of the formula (I) wherein X is O or S; and R1-R4 are defined in the claims as inhibitors of glyoxalase I and/or II, pharmaceutical compositions comprising one or more compounds according to formula (I) and the use of one or more compounds according to formula (I) for the treatment of diseases associated with increased glycolytic metabolism. In one embodiment, the disease is a fungal infection.Type: ApplicationFiled: April 13, 2006Publication date: December 4, 2008Inventors: Klaus Huse, Gerd Birkenmeier, Monika Birkenmeier
-
Patent number: 7445931Abstract: The present invention provides compositions and methods for human neural cell production. More particularly, the present invention provides cellular differentiation methods employing amphiphilic lipid compounds, preferably ceramide analogs of the ?-hydroxyalkylamine type and optionally employing an essentially serum free MEDII conditioned medium for the generation of human neural cells from pluripotent human cells. The methods alternatively comprise modulating apoptosis by modifying the levels of PAR-4, with or without the presence of amphiphilic lipid compounds and optionally employing MEDII conditioned medium. The methods alternatively encompass modulating apoptosis by modulating the intracellular concentration of endogenous lipid second messengers, such as ceramide.Type: GrantFiled: September 25, 2003Date of Patent: November 4, 2008Assignees: Bresagen, Inc., Medical College of Georgia Research InstituteInventors: Brian G. Condie, Erhard Bieberich
-
Publication number: 20080194681Abstract: Disclosed herein are carbonyl compounds of Formula: (I) as described herein. Compounds as modulators of his-tone deacetylase (HDAC), pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.Type: ApplicationFiled: December 9, 2005Publication date: August 14, 2008Applicant: Kalypsys, Inc.Inventors: James Malecha, Stewart Noble, Christian Hassig, Paul Wash, Brandon Wiley, Charles Lawrence, Timothy Hoffman, Celine Bonnefous, NIcholas Smith
-
Publication number: 20080188557Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, acne, alopecia, hirsutism, a wound, prostate cancer, bladder cancer, liver cancer, breast cancer and Kennedy's disease.Type: ApplicationFiled: January 8, 2008Publication date: August 7, 2008Inventors: Charles C.Y. Shih, Qian Shi, Hui-Kang Wang, Ching-Yuan Su
-
Patent number: 7407985Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.Type: GrantFiled: January 17, 2006Date of Patent: August 5, 2008Assignee: Canbas Co., Ltd.Inventors: Takumi Kawabe, Hidetaka Kobayashi
-
Patent number: 7405238Abstract: Drugs intended for absorption in the stomach or upper intestinal tract are administered in oral drug delivery systems in conjunction with any of various substances that have been discovered to function as potent agents for inducing the fed mode. By inducing the onset of the fed mode, these agents cause the stomach to prolong its retention of the drug delivery system, which is either large enough to be retained in the stomach during the fed mode or swells or expands to such a size upon ingestion. The fed mode inducing agents include the following compounds and their salts: glycine and glycylglycine, xylitol and related sugar alcohols, sodium and other metal docusates, ?-casomorphins, ?-lipoic acid and similarly structured acids, 2,2-diaryl-4-(4?-aryl-4?-hydroxypipendino)butyramides, arginine, Trp-Trp, alkylpyridinium halides, dihydroxybenzoic acids, and potent sweeteners such as aspartame, aspartic acid, acesulfame, and stevioside.Type: GrantFiled: September 4, 2002Date of Patent: July 29, 2008Assignee: Depomed Inc.Inventors: Micheline Markey, John W. Shell, Bret Berner
-
Publication number: 20080161395Abstract: The invention relates to a new class of compounds with action inhibiting carnitine palmitoyl transferase (CPT), pharmaceutical compounds which contain at least one new compound according to the invention, and their therapeutic use in the treatment of hyperglycaemic conditions such as diabetes and the pathologies associated with it, congestive heart failure and obesity.Type: ApplicationFiled: February 13, 2006Publication date: July 3, 2008Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Fabio Giannessi, Emanuela Tassoni, Maria Ornella Tinti, Roberto Conti, Natalina Dell'Uomo, Tiziana Brunetti